NASDAQ:PRQR

ProQR Therapeutics Competitors

$6.23
-0.29 (-4.45 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.17
Now: $6.23
$6.49
50-Day Range
$4.35
MA: $5.62
$9.22
52-Week Range
$3.40
Now: $6.23
$9.46
Volume1.46 million shs
Average Volume3.39 million shs
Market Capitalization$312.78 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73

Competitors

ProQR Therapeutics (NASDAQ:PRQR) Vs. PLRX, KNSA, PHAT, INVA, CDMO, and STTK

Should you be buying PRQR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to ProQR Therapeutics, including Pliant Therapeutics (PLRX), Kiniksa Pharmaceuticals (KNSA), Phathom Pharmaceuticals (PHAT), Innoviva (INVA), Avid Bioservices (CDMO), and Shattuck Labs (STTK).

ProQR Therapeutics (NASDAQ:PRQR) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Valuation and Earnings

This table compares ProQR Therapeutics and Pliant Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-4.02
Pliant Therapeutics$57.05 million21.24$-630,000.00N/AN/A

Pliant Therapeutics has higher revenue and earnings than ProQR Therapeutics.

Analyst Ratings

This is a summary of recent recommendations for ProQR Therapeutics and Pliant Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00503.00
Pliant Therapeutics00503.00

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 424.34%. Pliant Therapeutics has a consensus price target of $45.50, indicating a potential upside of 34.22%. Given ProQR Therapeutics' higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Pliant Therapeutics.

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 79.5% of Pliant Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Pliant Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-62.92%-47.69%
Pliant Therapeutics20.83%16.55%8.33%

Summary

Pliant Therapeutics beats ProQR Therapeutics on 6 of the 7 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

ProQR Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.

Valuation and Earnings

This table compares ProQR Therapeutics and Kiniksa Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-4.02
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.92

Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for ProQR Therapeutics and Kiniksa Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00503.00
Kiniksa Pharmaceuticals00303.00

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 424.34%. Kiniksa Pharmaceuticals has a consensus price target of $37.00, indicating a potential upside of 109.16%. Given ProQR Therapeutics' higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Kiniksa Pharmaceuticals.

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 42.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 70.6% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-62.92%-47.69%
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

Summary

ProQR Therapeutics beats Kiniksa Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

ProQR Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Valuation and Earnings

This table compares ProQR Therapeutics and Phathom Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-4.02
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.75

ProQR Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for ProQR Therapeutics and Phathom Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00503.00
Phathom Pharmaceuticals10402.60

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 424.34%. Phathom Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 37.70%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Phathom Pharmaceuticals.

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 39.8% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-62.92%-47.69%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Summary

ProQR Therapeutics beats Phathom Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

ProQR Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Valuation and Earnings

This table compares ProQR Therapeutics and Innoviva's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-4.02
Innoviva$261.02 million4.54$157.29 million$1.438.18

Innoviva has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for ProQR Therapeutics and Innoviva, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00503.00
Innoviva10001.00

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 424.34%. Innoviva has a consensus price target of $10.00, indicating a potential downside of 14.53%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Innoviva.

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 71.5% of Innoviva shares are held by institutional investors. 0.3% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Innoviva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-62.92%-47.69%
Innoviva67.16%53.99%28.92%

Summary

Innoviva beats ProQR Therapeutics on 9 of the 13 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Avid Bioservices (NASDAQ:CDMO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Volatility & Risk

ProQR Therapeutics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Avid Bioservices has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500.

Valuation and Earnings

This table compares ProQR Therapeutics and Avid Bioservices' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-4.02
Avid Bioservices$59.70 million19.76$-10,470,000.00($0.27)-71.81

Avid Bioservices has higher revenue and earnings than ProQR Therapeutics. Avid Bioservices is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for ProQR Therapeutics and Avid Bioservices, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00503.00
Avid Bioservices00303.00

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 424.34%. Avid Bioservices has a consensus price target of $17.3333, indicating a potential downside of 10.61%. Given ProQR Therapeutics' higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Avid Bioservices.

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 58.2% of Avid Bioservices shares are held by institutional investors. 1.7% of Avid Bioservices shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-62.92%-47.69%
Avid Bioservices0.20%0.31%0.13%

Summary

Avid Bioservices beats ProQR Therapeutics on 9 of the 12 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.

Profitability

This table compares ProQR Therapeutics and Shattuck Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProQR TherapeuticsN/A-62.92%-47.69%
Shattuck LabsN/AN/AN/A

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares ProQR Therapeutics and Shattuck Labs' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR TherapeuticsN/AN/A$-63,560,000.00($1.55)-4.02
Shattuck LabsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for ProQR Therapeutics and Shattuck Labs, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProQR Therapeutics00503.00
Shattuck Labs00503.00

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 424.34%. Shattuck Labs has a consensus price target of $45.25, indicating a potential upside of 60.29%. Given ProQR Therapeutics' higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Shattuck Labs.


ProQR Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Gap Down
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58-0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54-1.6%$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78-0.7%$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Gap Up
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27News Coverage
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
Humanigen logo
HGEN
Humanigen
1.6$17.25-1.9%$922.56 millionN/A0.00
Radius Health logo
RDUS
Radius Health
1.3$19.49-2.0%$913.96 million$173.32 million-7.99News Coverage
Prothena logo
PRTA
Prothena
2.3$22.78-3.1%$911.34 million$810,000.00-8.90Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25-2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$35.87-0.4%$881.43 millionN/A-10.64Analyst Report
Gap Down
Merus logo
MRUS
Merus
1.6$23.06-1.0%$879.21 million$31.13 million-7.51Analyst Report
Analyst Revision
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$16.75-0.0%$861.92 millionN/A0.00
Affimed logo
AFMD
Affimed
1.6$9.74-19.0%$860.30 million$23.96 million-16.51Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Epizyme logo
EPZM
Epizyme
1.8$8.37-0.6%$851.94 million$23.80 million-3.75
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$17.89-0.6%$848.58 million$322.36 million127.79
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.33-1.3%$810.86 million$296.70 million47.61
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.57-7.5%$791.51 millionN/A0.00Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37-1.1%$775.18 million$322.07 million-5.11
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.95-4.7%$753.06 million$148.36 million-7.00Gap Down
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$10.02-1.2%$747.83 million$40.89 million-3.46
Veru logo
VERU
Veru
1.4$10.35-0.3%$744.29 million$42.59 million-36.96
Ardelyx logo
ARDX
Ardelyx
1.6$7.44-5.6%$734.18 million$5.28 million-7.37Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17-5.3%$731.97 million$252 million-2.27Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.45-2.1%$723.99 million$12.52 million-14.82News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.82-1.8%$716.29 million$2.22 million-16.59
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32-2.1%$714.48 million$150,000.00-4.74Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$3.05-3.3%$708.43 million$64.61 million-4.49Upcoming Earnings
Analyst Upgrade
Gap Down
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.50-0.0%$686.58 million$19.56 million-19.78High Trading Volume
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.